TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
The American College of Cardiology (ACC) annual meeting is the premier source for the latest cardiac science. #ACC22

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

How the continued rise of TAVR has impacted SAVR outcomes

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

The mitral valve visualized by a a GE NuVision 4D intra-cardiac echo (ICE) catheter a life-like surgical rendering technology on the Vivid E95 cardiac ultrasound system. The catheter was co-developed with Biosense Webster to perform EP procedures. It also can be used in place of TEE in structural heart procedures to eliminate the need for an interventional echocardiography.  #ACC22

Photo Gallery: ACC 2022 in pictures

Click through a wide variety of snapshots from ACC.22 in Washington, D.C. 

TAVR vs. surgery, FFR-guided PCI and DCB safety: Day 3 at ACC.22

Read our in-person coverage of the final day of ACC.22.

Same-day discharge after TAVR is feasible and safe, new Cleveland Clinic study confirms

Cleveland Clinic turned to same-day discharge after TAVR during the COVID-19 pandemic, finding considerable success. 

Q&A U.S. and European Valvular Heart Disease Guidelines: Lessons from Across the Pond

Sponsored by Medtronic

“Good harmony” is the way John P. Erwin III, MD, describes the synergy of the 2021 ESC/EACTS Guidelines for the management of valvular heart disease (VHD) released in August along with the ACC/AHA guidelines that rolled in December 2020.

When infective endocarditis after TAVR is most likely to be fatal

Researchers reviewed data from more than 900 patients, sharing their research in the American Journal of Cardiology.

Displaying 337 - 344 of 472

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.